AI assistant
Aptevo Therapeutics Inc. — Director's Dealing 2018
Mar 14, 2018
35422_dirs_2018-03-13_91d6d867-5361-4994-ba72-328919ce2f37.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Aptevo Therapeutics Inc. (APVO)
CIK: 0001671584
Period of Report: 2018-03-09
Reporting Person: Stromatt Scott C (Chief Medical Officer and SVP)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-03-09 | Common Stock | M | 13892 | — | Acquired | 204737 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-03-09 | Employee Stock Options (Right to Buy) | $3.13 | A | 67400 | Acquired | 2028-03-09 | Common Stock (67400) | Direct |
| 2018-03-09 | Restricted Stock Unit | $ | M | 13892 | Disposed | Common Stock (13892) | Direct |
Footnotes
F1: Each RSU converts into the Issuer's common stock on a one-for-one basis.
F2: On March 9, 2018, the reporting person was granted 67,400 stock options vesting in three equal annual installments beginning on the first anniversary of the grant date.
F3: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 10, 2015. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016, each RSU was adjusted and assumed by the Issuer. The RSUs fully vested as of March 9, 2018.